NervGen Pharma (DE:9UA)
FRANKFURT:9UA
9UA Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
9UA Stock 12 Month Forecast
Average Price Target
€10.21
▲(191.62% Upside)
| Highest Price Target€15.44 | Average Price Target€10.21 | Lowest Price Target€4.72 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Stifel Nicolaus
€5.15
Buy
47.04%
Upside
Reiterated
05/21/26
H.C. Wainwright
€15.44
Buy
341.11%
Upside
Reiterated
04/28/26
Lucid Capital
€15.44
Buy
341.11%
Upside
Initiated
04/15/26
Research Capital
€4.72
Buy
34.78%
Upside
Reiterated
04/10/26
Is NervGenPharma still undervalued?Uddin said the pivotal study is expected to enroll about 150 patients at roughly 60 sites across the United States and Canada, with startup activity already underway and trial initiation still expected around mid-2026. He said enrollment could be completed in the second half of 2027, with topline data in the first half of 2028 and a potential NDA filing in the second half of 2028.
Maxim Group
€8.58→€10.29
Buy
194.07%
Upside
Assigned
04/09/26
Paradigm
€3.11→€6.03
Buy
72.24%
Upside
Reiterated
06/17/25
Raymond James
€2.16→€3.73
Buy
6.54%
Upside
Reiterated
06/11/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Stifel Nicolaus
€5.15
Buy
47.04%
Upside
Reiterated
05/21/26
H.C. Wainwright
€15.44
Buy
341.11%
Upside
Reiterated
04/28/26
Lucid Capital
€15.44
Buy
341.11%
Upside
Initiated
04/15/26
Research Capital
€4.72
Buy
34.78%
Upside
Reiterated
04/10/26
Is NervGenPharma still undervalued?Uddin said the pivotal study is expected to enroll about 150 patients at roughly 60 sites across the United States and Canada, with startup activity already underway and trial initiation still expected around mid-2026. He said enrollment could be completed in the second half of 2027, with topline data in the first half of 2028 and a potential NDA filing in the second half of 2028.
Maxim Group
€8.58→€10.29
Buy
194.07%
Upside
Assigned
04/09/26
Paradigm
€3.11→€6.03
Buy
72.24%
Upside
Reiterated
06/17/25
Raymond James
€2.16→€3.73
Buy
6.54%
Upside
Reiterated
06/11/25
Best Analysts Covering NervGen Pharma
3 Months
Success Rate
2/3 ratings generated profit
Average Return
+11.27%
Copying Michael W. Freeman's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +11.27% per trade.
1 Year
Success Rate
2/3 ratings generated profit
Average Return
+81.27%
Copying Michael W. Freeman's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +81.27% per trade.
2 Years
Success Rate
4/11 ratings generated profit
Average Return
-1.82%
Copying Justin Keywood's trades and holding each position for 2 Years would result in 36.36% of your transactions generating a profit, with an average return of -1.82% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
9UA Analyst Recommendation Trends
Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
1
6
7
6
Buy
0
1
5
5
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
2
11
12
10
Each month's total comprises the sum of three months' worth of ratings.
9UA Financial Forecast
9UA Stock Forecast FAQ
What is DE:9UA’s average 12-month price target, according to analysts?
Based on analyst ratings, NervGen Pharma’s 12-month average price target is 10.21.
What is DE:9UA’s upside potential, based on the analysts’ average price target?
NervGen Pharma has 191.62% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NervGen Pharma a Buy, Sell or Hold?
NervGen Pharma has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is NervGen Pharma’s share price target?
The average share price target for NervGen Pharma is 10.21. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €15.44 ,and the lowest forecast is €4.72. The average share price target represents 191.62% Increase from the current price of €3.5.
The highest analyst share price target is €15.44 ,and the lowest forecast is €4.72. The average share price target represents 191.62% Increase from the current price of €3.5.
What do analysts say about NervGen Pharma?
NervGen Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of NervGen Pharma?
To buy shares of DE:9UA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.